Payment overview · 2025
General Payments
$95.48
5 reported records · 5 companies
Healthcare provider profile · identity verified
Yolanda Bledsoe, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORISSANT, MO · NPI 1396855391
Verified facts
What the public records show
CMS Open Payments records show Yolanda Bledsoe, MD received $95.48 in general payments during 2025 across 5 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $27.83 | 29.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.05 | 23.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.30 | 17.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.29 | 16.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.01 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.48 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 836 | 244 |
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 206 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 547 | 156 |
| Metformin Hcl | Metformin Hcl | 331 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 104 |
| Losartan Potassium | Losartan Potassium | 309 | 91 |
| Gabapentin | Gabapentin | 308 | 89 |
| Lisinopril | Lisinopril | 299 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 273 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 76 |
| Furosemide | Furosemide | 262 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 79 |
| Carvedilol | Carvedilol | 231 | 68 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 200 | 57 |
| Potassium Chloride | Potassium Chloride | 197 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 195 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 186 | 70 |
| Omeprazole | Omeprazole | 164 | 59 |
| Eliquis | Apixaban | 160 | 36 |
| Famotidine | Famotidine | 159 | 50 |
| Mounjaro | Tirzepatide | 147 | 28 |
| Meloxicam | Meloxicam | 146 | 48 |
| Metformin Hcl Er | Metformin Hcl | 140 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 19 |
| Allopurinol | Allopurinol | 124 | 40 |
| Spironolactone | Spironolactone | 123 | 42 |
| Simvastatin | Simvastatin | 120 | 40 |
| Mirtazapine | Mirtazapine | 117 | 36 |
| Nifedipine Er | Nifedipine | 116 | 30 |
| Tramadol Hcl | Tramadol Hcl | 116 | 41 |
| Azelastine Hcl | Azelastine Hcl | 113 | 43 |
| Alendronate Sodium | Alendronate Sodium | 112 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 30 |
| Buspirone Hcl | Buspirone Hcl | 108 | 39 |
| Glipizide | Glipizide | 104 | 28 |
| Trazodone Hcl | Trazodone Hcl | 104 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 32 |
| Jardiance | Empagliflozin | 95 | 22 |
| Januvia | Sitagliptin Phosphate | 90 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 27 |
| Pregabalin | Pregabalin | 87 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 15 |
| Ezetimibe | Ezetimibe | 82 | 31 |
| Ozempic | Semaglutide | 80 | 13 |
| Glimepiride | Glimepiride | 79 | 22 |
| Bupropion Xl | Bupropion Hcl | 75 | 26 |
| Methylprednisolone | Methylprednisolone | 75 | 70 |
| Donepezil Hcl | Donepezil Hcl | 73 | 22 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Nystatin | Nystatin | 70 | 30 |
| Rybelsus | Semaglutide | 70 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 21 |
| Farxiga | Dapagliflozin Propanediol | 67 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 18 |
| Cephalexin | Cephalexin | 65 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 16 |
| Chlorthalidone | Chlorthalidone | 50 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 12 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 17 |
| Valsartan | Valsartan | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 46 | 13 |
| Enalapril Maleate | Enalapril Maleate | 44 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Atenolol | Atenolol | 37 | 12 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Baclofen | Baclofen | 35 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Clotrimazole | Clotrimazole | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Klor-Con M20 | Potassium Chloride | 31 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 20 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 22 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Finasteride | Finasteride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pimecrolimus | Pimecrolimus | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.48 · 5 records | SANOFI-AVENTIS U.S. LLC | AREXVY, CAMZYOS, EVENITY, INCEPTIV, PROLIA, SHINGRIX, TZIELD | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error